Clinical Trial Update: A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

View source ↗

Summary

A real-world comparative study is evaluating donanemab plus usual care versus usual care alone in US participants with early symptomatic Alzheimer's disease; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Donanemab (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Status: RECRUITING